Canada: Life Sciences, Biotechnology & Nanotechnology

Dans une décision importante pour le secteur canadien des sciences de la vie, la Cour suprême du Canada a confirmé, le 17 juillet 2026, que les schémas posologiques pharmaceutiques innovants peuvent constituer un objet brevetable.

Healthcare M&A in Canada is experiencing a significant transformation, with total deal values surging from $4.5 billion to over $12 billion as pharmaceutical companies navigate patent cliffs and pursue revenue-generating assets. As artificial intelligence reshapes transaction assessments and intellectual property diligence becomes increasingly complex, dealmakers must adopt multidisciplinary approaches that integrate regulatory, data governance, and technology considerations into their strategic evaluations

In an important decision for Canada’s life sciences industry, on July 17, 2026, the Supreme Court of Canada confirmed that innovative pharmaceutical dosing regimens can constitute patentable subject matter.

Health Canada released a notice to industry on April 24, 2026, outlining that manufacturers must use the Regulatory Enrolment Process (REP) and Common Electronic Submission Gateway (CESG) for medical device transactions as of April 1, 2026. As we previously reported, manufacturers of medical devices could voluntarily use the REP and CESG for medical device regulatory transactions as of July 2024.

In January and February 2026, Health Canada released the Quarterly Report for Q2 2025-2026 (July through September 2025) and for Q3 2025-2026 (October through December 2025).

As part of a deeply interconnected global sector, the life sciences industry in Canada is undergoing significant change alongside broad macroeconomic and geopolitical shifts.

The Patented Medicine Price Review Board (PMPRB) has opened a public consultation on proposed Practice Directions governing PMPRB hearings.

The Federal Court has dismissed a request to certify a proposed class proceeding against a large number of generic...

La Cour fédérale a rejeté une requête pour obtenir l'autorisation d'exercer un recours collectif contre un grand nombre de fabricants de médicaments génériques nommés comme défenderesses ...